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Abstract
Background: Multiple sclerosis (MS) affects the integrity of the blood-brain barrier (BBB). Contrast-enhanced T1 weighted
magnetic resonance imaging (MRI) is widely used to characterize location and extent of BBB disruptions in focal MS lesions.
We employed quantitative T1 measurements before and after the intravenous injection of a paramagnetic contrast agent to
assess BBB permeability in the normal appearing white matter (NAWM) in patients with relapsing-remitting MS (RR-MS).
Methodology/Principal Findings: Fifty-nine patients (38 females) with RR-MS undergoing immunomodulatory treatment
and nine healthy controls (4 females) underwent quantitative T1 measurements at 3 tesla before and after injection of
a paramagnetic contrast agent (0.2 mmol/kg Gd-DTPA). Mean T1 values were calculated for NAWM in patients and total
cerebral white matter in healthy subjects for the T1 measurements before and after injection of Gd-DTPA. The pre-injection
baseline T1 of NAWM (945655 [SD] ms) was prolonged in RR-MS relative to healthy controls (903623 ms, p = 0.028). Gd-
DTPA injection shortened T1 to a similar extent in both groups. Mean T1 of NAWM was 866647 ms in the NAWM of RR-MS
patients and 824613 ms in the white matter of healthy controls. The regional variability of T1 values expressed as the
coefficient of variation (CV) was comparable between the two groups at baseline, but not after injection of the contrast
agent. After intravenous Gd-DTPA injection, T1 values in NAWM were more variable in RR-MS patients (CV = 0.19860.046)
compared to cerebral white matter of healthy controls (CV = 0.16660.018, p = 0.046).
Conclusions/Significance: We found no evidence of a global BBB disruption within the NAWM of RR-MS patients
undergoing immunomodulatory treatment. However, the increased variation of T1 values in NAWM after intravenous Gd-
DTPA injection points to an increased regional inhomogeneity of BBB function in NAWM in relapsing-remitting MS.
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Introduction
Multiple sclerosis (MS) is an autoimmune disease affecting the
central nervous system and is one of the major neurologic diseases
in the Western world. MS disrupts the integrity of the blood-brain
barrier (BBB) enabling active components of the immune system
to enter the brain parenchyma [1]. Subsequently a cascade of
immunological events [2] leads to the characteristic lesions seen on
magnetic resonance images (MRI) of the brain or spinal cord [3].
There is evidence that this disruption of the BBB is of major
relevance in the early dynamics of the focal MS lesions [2].
Whether early disruption of the BBB allows for lesions to develop
or whether an early inflammatory event causes the BBB disruption
is still a matter of debate as the two phenomena seems to occur in
parallel [4].
The local disruption of the BBB can be captured with T1
weighted MRI after intravenous injection of a Gadolinium (Gd)
chelated paramagnetic contrast agent [5]. The contrast agent has
a shortening effect on the longitudinal relaxation time (T1) of
neighbouring water protons. Since the contrast agent penetrates
the disrupted BBB and accumulates locally in the affected brain
parenchyma it causes an increase in signal intensity (i.e., contrast
enhancement) on T1 weighted images.
In a clinical setting, contrast-enhanced T1 weighted MRI is
particularly useful to detect focal BBB disruption in active MS
lesions. This virtue makes contrast-enhanced T1 weighted MRI
a sensitive tool to detect dissemination of the disease process in
space and time, which is essential for making an early diagnosis of
MS [6]. The number and location of lesions [6] or their total
volume [7] is often used as a surrogate marker for disease severity
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even though they show only moderate correlations with both
cognitive impairments [8,9,10] and neurological disabilities [9,11].
This modest correlation might be due to unknown pathological
severity of the lesions and to the fact that symptoms also depend
on the location of the lesions. Further, as demonstrated by various
quantitative MRI techniques, there is converging evidence that the
pathological process extends into the normal appearing white
matter (NAWM). Diffusion MRI revealed altered fiber structure in
the NAWM [12], while proton-magnetic resonance spectroscopy
(MRS) provided changes in the spectrum compatible with axonal
loss [13]. MRI has also yielded a reduction of magnetization
transfer ratios which has been attributed to a destruction of
macromolecules [14]. Histopathological studies have shown
increased levels of gliosis, demyelination and cellular infiltration
[15,16] which might be the histological correlate for the alterations
revealed by MRI and MRS. Recent studies, however, suggest that
changes in the NAWM may primarily be evident in patients with
progressive MS [16,17].
The structural changes in NAWM have been shown to correlate
with clinical disability [9,18,19,20]. This converging evidence
suggests that pathological processes within the NAWM are
contributing to the clinical disability, yet it is unclear to what
extent the BBB is disrupted in NAWM and whether such
disruption has impact on the functional impairment of MS
patients. In this context, it is relevant to recall that the majority of
MS patients receive immunomodulatory treatment, which might
stabilize BBB integrity in NAWM. A disruption of the BBB in
NAWM has been demonstrated in a histopathological study [21].
However, this is in contrast with an in vivo MRI study which
included 33 patients with either RR-MS or secondary or primary
progressive MS and five healthy control subjects [22]. In that
study, the quantification of contrast enhancement following the
intravenous administration of 0.3 mmol/kg Gd-DTPA yielded no
evidence for a disruption of BBB integrity in the NAWM [22].
In general, intravenous injection of a paramagnetic contrast
agent shortens T1 throughout the brain – including the white
matter of healthy controls [23]. This effect is therefore not
specifically related to pathology. Using a new approach to
quantitatively measure T1 values, we aimed at assessing differ-
ences in contrast agent accumulation in the NAWM of patients
with relapsing-remitting MS (RR-MS) and cerebral white matter
of healthy age-matched controls. We hypothesized that compared
to healthy controls a diffuse disruption of the BBB in MS patients
would cause a greater change in the mean T1 value.
Results
Quantitative multi-point T1 measurements revealed significant-
ly higher mean T1 values in NAWM in patients with RR-MS
compared to white matter in healthy controls, both before
(t = 2.255, p = 0.028, df = 67) and after (t = 2.676, p = 0.009,
df = 66) the injection of contrast agent (Figure 1, Table 1). The
NAWM in MS patients (t = 16.51, p,,0.001) and the cerebral
white matter in healthy controls (t = 8.36, p,,0.001) showed
a significant decrease in the mean T1 value after injection of
0.2 mmol/kg Gd-DTPA (Figures 2 and 3). The reduction in mean
T1 value was comparable between patients and healthy controls.
Accordingly, the ANOVA showed a main effect of group
(F = 5.625, p = 0.021) and ‘‘time’’ (before vs. after Gd-DTPA
injection) (F = 1,140, p,,0.001) but no interaction between
group and time.
The mean T1 values of each participant at pre-injection
baseline were plotted against the mean T1 values after injection of
contrast agent (Figure 2). It is evident from this plot that the
injection of contrast agent consistently reduced the mean T1 value
in both healthy controls and patients. The data of the nine healthy
control subjects showed limited variation as all data points
clustered in the lower left corner (Figure 2). In contrast, the T1
data of the patient group was more scattered indicating stronger
between-subjects variability in MS patients. The scatter plot of the
T1 values before and after contrast agent injection did not reveal
a clustered distribution of the data that would allow a delineation
of specific subgroups (Figure 2). No significant differences in the
response to Gd-DTPA injection could be detected between MS
patients with an expanded disability status scale (EDSS) score #2
and patients with an EDSS score of .2. Accordingly, we did not
find any correlations between EDSS or age and T1 values before
or after injection of contrast agent. Neither did EDSS or age
correlate with the change in T1 caused by injection of contrast
agent (not shown).
If MS impaired the BBB integrity only in some spots of the
NAWM, one might expect that MS patients would show more
heterogeneous T1 values within NAWM after contrast agent
injection. Therefore, we also assessed the coefficient of variation of
T1 values in NAWM at baseline and after intravenous Gd-DTPA
injection (Figures 4 and 5, Table 1). The regional variability of T1
values as expressed by the coefficient of variation was comparable
between the two groups at baseline (t = 0.60, p = 0.56) but not after
injection of the contrast agent (t = 2.04, p = 0.046). Accordingly,
a two-factorial ANOVA with the between-subject factor ‘‘group’’
(controls vs patients) and the within-subject factor ‘‘time’’ (before
vs. after Gd-DTPA injection) did not reveal a main effect of group
(F = 0.007, p = 0.934). However, we did see a main effect of time
(F = 34.2, p,,0.001) as well as an interaction between group and
time (F = 9.25, p = 0.003).
Discussion
This MRI study yielded three main findings: First, T1 values in
NAWM of patients with RR-MS were significantly higher
compared to the T1 values of the cerebral white matter in healthy
controls. This was the case at baseline as well as after injection of
Gd-DTPA. Second, Gd-DTPA injection consistently reduced the
mean T1 value in NAWM of patients with RR-MS as well as in
white matter of the controls. In contrast to our research
hypothesis, the change in T1 value was comparable in size in
patients and healthy controls. Third, the heterogeneity of the T1
values after the injection of contrast agent was higher in patients,
suggesting a more variable BBB function in the various subregions
of the NAWM.
Structural Changes in the Normal Appearing White
Matter in Multiple Sclerosis
Several groups employed quantitative magnetic resonance
methods to demonstrate a diffuse involvement of NAWM in
MS. Using proton MRS, Sarchielli et al. found reduced levels of
N-acetyl-aspartate (NAA) within the NAWM compared to white
matter of healthy controls [13]. Since NAA is considered a specific
marker of functional neurons, lower NAA levels within the
NAWM indicate a reduction in axonal density in this area.
Accordingly, Filippi et al. [12] found a significantly higher mean
diffusivity in the NAWM of patients compared to white matter of
controls using diffusion weighted MRI. The NAWM also displays
a reduced magnetization transfer ratio (MTR) [14]. The MTR
reflects the transfer of magnetization between protons in
macromolecules and protons in surrounding free water and is
associated with axonal density of the brain tissue [24,25]. These
neuroimaging data are in agreement with histological findings of
Blood-Brain Barrier in Multiple Sclerosis
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increased levels of gliosis, demyelination and cell infiltrations
within the NAWM [15,16]. Together, these reports give evidence
of pathological changes within the NAWM at structural as well as
at functional levels. Further, the clinical relevance of these NAWM
changes is emphasized by their correlations with neuropsycholo-
gical measures [18,26].
The quantitative T1 measurements at baseline showed higher
mean T1 values in NAWM of patients with RR-MS compared to
the T1 values of the cerebral white matter in healthy controls,
lending further support to the notion that the structure of the
NAWM is altered in MS. Our baseline T1 measurements further
revealed that the coefficient of variation of the T1 values in the
NAWM did not differ between MS patients and healthy controls.
We therefore infer that the increase in T1 values in MS patients is
diffuse rather than regional.
The findings are in good agreement with a previous MRI study
in which T1 values in NAWM were reported to be increased in
MS [27]. A voxel-based MRI study at 1.5 T focused on the spatial
pattern of T1 abnormalities in MS. In that study, large parts of the
NAWM displayed increased T1 values and the voxels with
increased T1 values were distributed throughout the brain without
a particular anatomic preference [28]. Another 1.5 T MRI study
found significantly higher T1 values in MS patients, but only in the
occipital part of the NAWM [29]. It needs to be mentioned though
that not all studies have found significantly higher mean T1 values
in RR-MS [30].
Integrity of the Blood-brain Barrier in the NAWM
RR-MS patients showed a consistent reduction of mean T1
value in NAWM after Gd-DTPA injection. This reduction
matched the one found in white matter of healthy controls.
Accordingly, mean T1 values in NAWM were higher in RR-MS
patients than in healthy controls, both at baseline and after
contrast agent injection. This is in accordance with the MRI study
by Silver et al. [22] in which 12 RR-MS patients also showed no
difference in T1 value change after injection of 0.3 mmol/kg Gd-
DTPA relative to five healthy controls.
The injection of contrast agent increased the variation of T1
values within the NAWM of patients but not in the cerebral white
matter of healthy controls (Figure 5). In other words, the mean
decrease in T1 value was normal in NAWM, but local changes in
T1 value induced by contrast agent injection were more variable
in RR-MS patients. Two mechanisms with opposite effects on the
T1 value might account for the increased heterogeneity of T1
values in NAWM after contrast agent injection. While regional
disruptions of the BBB may result in an increased amount of GD-
DTPA in the tissue and thereby stronger reductions of the T1
value after contrast injection, a reduced blood compartment in
NAWM might lead to a decreased amount of Gd-DTPA and
Figure 1. T1 values of the healthy controls and the patients. The plot shows mean T1 (s) and 95% confidence intervals. The injection of
contrast agent significantly reduced T1 for both patients and controls. Compared to healthy white matter, the T1 value in NAWM of patients was
higher both before and after the injection of contrast agent.
doi:10.1371/journal.pone.0056375.g001
Figure 2. T1 values before and after the injection of contrast
agent. For each healthy control and each patient, the mean T1 of the
white matter and NAWM, respectively was calculated. Each subject is
thus represented by a marker in the corresponding position. All
individual subjects had lower T1 values after the injection of contrast
agent (i.e. all markers are plotted below the line representing y = x).
doi:10.1371/journal.pone.0056375.g002
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thereby attenuate the reduction in T1 value. If these two
mechanisms are differentially expressed in the NAWM, this may
increase the heterogeneity of T1 values in the presence of a normal
reduction in mean T1-values. Whatever the mechanism may be,
the increased variability in T1 values after contrast agent injection
raises the possibility that BBB dysfunction in the NAWM is locally
rather than globally expressed. Further, it is possible that between-
group differences were partly concealed because of partial volume
effects and inter-slice gaps. We might have observed larger
coefficients of variation by reducing the voxel size and eliminating
the gaps between consecutive slides. However, smaller voxel sizes
would have resulted in a lower signal to noise ratio and/or an
increased acquisition time. The regional expression of BBB
function in NAWM requires further investigation.
In RR-MS patients, the decrease in mean T1 value was
comparable when splitting patients in two groups with an EDSS
score #2 or .2. This confirms a previous MRI study [22] and
speaks against a close correlation between global BBB integrity of
the NAWM and clinical impairment in MS.
We also wish to point out that all included patients were on
treatment with interferon beta or glatiramer acetate. We therefore
cannot exclude the possibility that the natural course of RR-MS
might be associated with a BBB dysfunction of NAWM, but that
this BBB disruption was reversed by immunomodulatory therapy.
Indeed, the fact that patients had been treated with interferon beta
and glatiramer acetate could very well reduce the probability of
detecting BBB disruptions, as immunomodulatory treatment
decreases the number of Gd-enhancing lesions [31,32]. Further,
the immunomodulatory treatment attenuates the natural in-
termittent inflammatory process of RR-MS patients and hereby
reduces the probability to detect subtle disruption of the BBB in
NAWM. Therefore, the present study provides no information
about BBB dysfuntion that might be observed during the natural
course of the disease. However, recruiting drug-naı¨ve patients that
do not receive any immunomodulatory treatment would not be
realistic in Denmark where practically all patients with MS are
treated with immunomodulatory drugs.
Figure 3. Change in T1 values caused by the injection of the contrast agent. The plot shows the mean change in T1 and 95% confidence
intervals. We found no difference between the two groups when evaluating the effect of contrast agent on the T1 value.
doi:10.1371/journal.pone.0056375.g003
Table 1. Group data for healthy controls and patients with relapsing-remitting multiple sclerosis (RR-MS).
Healthy control subjects Patients with RR-MS
Number (male/female) 9 (5/4) 59 (21/38)
Age 34.569.4 years 38.268.1 years
Mean T1 (baseline) 903623 ms 945655 ms
Mean T1 (Gd-DTPA) 824613 ms 866647 ms
Coefficient of variation (baseline) 0.17860.088 0.16060.035
Coefficient of variation (Gd-DTPA) 0.16660.018 0.19860.046
Median EDSS score N/A 2.5
Number of voxels in analysis 898.46327.1 1410.16260.0
Lesion volumes N/A 11.3613.5 ml
For each healthy control and RR-MS patient, the mean and coefficient of variation of T1 values were calculated for measurements before and after intravenous injection
of 0.2 mmol/kg Gd-DTPA. Only the cerebral white matter of healthy controls and normally appearing white matter (NAWM) of patients were evaluated. Data are given
as mean 6 onefold SD.
doi:10.1371/journal.pone.0056375.t001
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Physiological Considerations
A number of other factors related to the nature of a BBB
damage need to be considered when interpreting the present
results. First, the early disruption of the BBB in an affected region
in MS might be caused by capillary wall adhesion of immunoac-
tive cells, which subsequently penetrate the endothelial cellular
layer and enter the cerebral tissue. At a later stage the leaky BBB
allows larger, hydrophilic substances like Gd-DTPA (molecular
weight: 938 g/mol [33]) to cross. Such passage could take place
either through gaps in damaged tight junctions between the
endothelial cells or by abnormal pinocytotic activity in the
endothelial cells allowing vesicular transport between the luminal
and abluminal membrane. Both pinocytosis [34] and abnormal
tight junctions [35] have been demonstrated in MS lesions.
Although histopathological studies by Kirk et al. [35] found no
statistically significant difference between tight junction abnor-
malities in normal controls and NAWM they did see a trend. The
extent to which these mechanisms occur within the NAWM
remains to be fully elucidated.
Second, focal tisue damage in demyelinated lesions leads to
a secondary loss of axons within the NAWM [36]. Such Wallerian
degeneration causes both structural and functional changes of the
axons that might contribute to all the above-mentioned measures
of diffusion, MTR and NAA levels. On the other hand, it is
unlikely that Wallerian degeneration would affect the BBB
function which would also be in line with the findings obtained
in the present study.
Third, timing of the data acquisition after injection of a contrast
agent is perhaps of importance to the reduction in the T1 value.
Silver et al. [22] found that within the white matter of healthy
controls, the reduction in T1 caused by the injection of contrast
agent vanished over the course of approximately 20 minutes.
Considering that healthy tissue is expected to have an intact BBB,
we would not expect such tissue to show a sustained effect of the
contrast agent. Lesions of MS patients, on the other hand, have
been shown to exhibit a prolonged enhancement up to an hour
[37]. It is likely that the duration of the effect of a contrast agent
within the NAWM is somewhere between that for lesions and
healthy tissue. A future study evaluating the rate at which T1
returns to its pre-contrast level could reveal differences between
NAWM in MS and white matter of healthy controls.
Methodological Considerations
The STEAM sequence used in the present study gives
a relatively fast, quantitative, multi-point T1 measurement robust
to inhomogeneity of the scanner’s radiofrequency field (B1
inhomogeneity). Combining the T1 value before and after the
injection of a contrast agent by calculating their mean difference
on an ROI basis, we obtained a measure of the BBB integrity
which is unbiased and potentially more sensitive compared to the
regular approach using T1 weighted images. A coregistration of
T1 maps before and after contrast injection would result in
Figure 4. Coefficient of variation of the healthy controls and the patients. The plot shows mean coefficient of variation and 95% confidence
intervals. After the injection of contrast agent the mean CV for patients was significantly larger than that of controls. This was not the case prior to the
injection of contrast agent.
doi:10.1371/journal.pone.0056375.g004
Figure 5. Coefficient of variation before and after the injection
of contrast agent. For each healthy control and each patient, the
coefficient of variation (CV) of the white matter and NAWM, respectively
was calculated. Each subject is thus represented by a marker in the
corresponding position (the dotted line represents y = x). It seems that
the CV of the patients are generally increased after the injection of the
contrast agent.
doi:10.1371/journal.pone.0056375.g005
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substantial data degradation since the voxelwise T1 differences
between the two scans are very sensitive to motions between scans.
Hence, a voxelwise comparison was not performed. However,
calculating a coefficient of variation on ‘‘delta-T1’’ values across
voxels for each subject might be a better measure to detect higher
regional variability of contrast-induced T1 changes in NAWM
relative to white matter in healthy controls. We used 0.2 mmol/kg
Gd-DTPA (so called ‘‘double dose’’) theoretically doubling the
contrast agent-induced signal change compared to a standard dose
[38].
Ideally, measurements of T1 values are independent from the
type of sequence or scanner. Often, however, one needs to
compromise on acquisition time or validity of the data. For
example, T1 measurements performed by varying the inversion
time (inversion recovery) typically require a relatively long
acquisition time. Alternative methods, based on variation of
sequence tip angles or repetition time TR, are limited by the
validity of assumed signal equations, which are most often
approximate. Further, the latter methods and other fast T1
measurements including the one used in the present study are
sensitive to B1 inhomogeneities [39] and valid B1 maps are needed
for correction.
Our reported T1 values are estimated from a 30-point
measurement using a novel MRI sequence. The performed
analysis assumed monoexponential T1 relaxation in each voxel.
No evidence of non-monoexponential relaxation at the ROI level
was found based on visual inspection of a subset of the fits. Also, an
extended model including a normal distribution of relaxation rates
was used. It was found to cause overfitting when applied to data at
the ROI level partially corrected for B1 inhomogeneity based on
an assumption of monoexponential relaxation at the voxel level.
This finding is consistent with monoexponential relaxation
behavior at the ROI and voxel levels but does not guarantee
either. Hence, a B1-corrected monoexponential model was
applied at the voxel level. We confer that acquiring fewer data
points on the T1 relaxation curve would suffice for a valid T1
estimate. Choosing few points optimally, however, would require
T1 values to be known a priori.
We found pre contrast T1 values in the group of healthy
controls to be 903 (623) ms, which is in good agreement with
previously reported values [30] but slightly higher than 832 ms as
reported by Wansapura et al. [40]. The study by Wansapura et al.
did not address the issue of transmit RF field (B1) inhomogeneities
that likely imply a spatially dependent bias in T1 estimates.
Concluding Remarks
BBB disruption is an early and very important event in the
development of MS lesions. The assessment of BBB disruption in
the NAWM is therefore of major importance to the diagnosis and
monitoring of MS and to the validation of new treatment strategies
– particularly because early treatment is known to improve the
clinical outcome [41]. The presented method is novel and
demonstrates a proof-of-principle applied on both patients and
controls.
Our quantative T1 measurements showed that RR-MS is
associated with diffuse structural abnormalities in NAWM as
evidenced by a decrease in T1 values, but this does not include
a diffuse disruption of BBB integrity. Since the present study
considered the NAWM as a whole, it remains to be explored to
what extent RR-MS is associated with more localized BBB
disruptions in NAWM and whether such changes can be detected
using quantitative and more sensitive contrast enhanced MR
techniques. Still our study indicates that localized changes in BBB
permeability may be present as we observed an increased
coefficient of variation of T1 following Gd-DTPA in NAWM of
the patients as compared to white matter in the controls.
Materials and Methods
Ethics Statement
The study was conducted in accordance with the Declaration of
Helsinki and was approved by The Danish National Committee
on Biomedical Research Ethics, Capital Region (KF 01-041/95
and KF 01-258762). Written informed consent was obtained from
all participants before they participated in the study.
Participants
We prospectively acquired MRI data from 59 patients (21
males, 38 females) with definite MS according to the revised
McDonald criteria [6] and a disease duration of at least six
months. Of the 59 patients, 38 were on treatment with interferon
beta and 21 received glatiramer acetate. Patients had a mean age
(6 standard deviation) of 38.2 (68.1) years. At the time of MRI
examination, patients had a median EDSS [42] score of 2.5,
ranging from 0 to 6.0. All patients had a relapsing-remitting
disease course. We also studied nine healthy controls (5 males, 4
females) with a mean age of 34.5 (69.4) years. No abnormalities
were detected in the healthy controls.
Magnetic Resonance Imaging
Scans were performed on a 3.0 tesla whole-body scanner (Trio,
Siemens, Erlangen, Germany) using an 8-channel head coil. Prior
to the imaging session an intravenous cannula was inserted and
connected to a line to avoid re-positioning of the participant after
the injection of the contrast agent.
Standard structural MRI measurements. A set of whole-
brain structural images was acquired before the injection of the
contrast agent. This included a Magnetisation Prepared Rapid
Acquisition Gradient Echo (MPRAGE) sequence with a repetition
time (TR) of 1540 ms, echo time (TE) of 3.9 ms, inversion time
(TI) of 800 ms and a 1 mm isotropic resolution (192 slices). We
additionally acquired T2 weighted brain images using a double
spin echo sequence (TE 115 ms, TR 8.8 s) with an in-plane
resolution of 0.760.7 mm2, a slice thickness of 4 mm, and
a refocusing tip angle of 163u. A Fluid Attenuated Inversion
Recovery (FLAIR) sequence was also acquired (TE 97 ms, TI
2500 ms and TR 10 s) with an in-plane resolution of
0.760.7 mm2, a slice thickness of 4 mm, and a refocusing flip
angle of 150u.
Quantitative T1 measurements. In all subjects, 0.2 mmol/
kg Gd-DTPA (Gadovist, Bayer Pharma AG, Germany) were
injected through an intravenous line. Quantitative T1 measure-
ments were acquired both before and approximately 20 min after
the injection of the contrast agent. For quantitative T1 measure-
ments, we chose a STimulated Echo Acquisition Mode (STEAM)
sequence, which enabled us to sample 30 points on the T1
relaxation curve in a whole-brain volume within 25 seconds. Echo
Planar Imaging (EPI) and acquisition of trains of stimulated echoes
were combined to provide voxel-wise multi-point T1 measure-
ments over many slices in a short time window. This novel
approach is time efficient, but the analysis requires care regarding
B1 inhomogeneity as addressed below.
The STEAM sequence corresponded to the sequence described
in [43], but diffusion gradients were replaced with shorter spoiler
gradients giving minimal diffusion weighting. The applied
STEAM sequence starts with two non-selective excitation pulses
having tip angles near 90u (Figure 6). The third excitation pulse of
the typical STEAM sequence is replaced with nested loops
Blood-Brain Barrier in Multiple Sclerosis
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involving repeated slice-selective small-angle excitations (a pulses),
each followed by EPI readout. The inner loop (slc) is over slices.
The number of repetitions in the outer loop (rep) determines how
many points are acquired on the T1 relaxation curves per STEAM
preparation. Since the EPI acquisition in different slices are time
shifted on the T1 relaxation curves, and in order to measure all
slices at the same time points after excitation, the whole sequence
is repeated (slc-order) with the excitation order of slices permuted
as many times as there are slices.
The parameters for the T1 measurement were: in-plane
resolution 3.463.4 mm2, slice thickness 8 mm (2 mm gaps), field
of view 220 mm, 15 slices (whole-brain volume), tip angle a= 15u,
TR 1740 ms, TE 40 ms and 30 evenly distributed STEAM
mixing times between 11 and 1,661 ms.
B1 measurement. Like other fast T1 measurements, the
developed T1 sequence is sensitive to the radiofrequency field (B1)
inhomogeneity [39], and must therefore be combined with B1
measurements to provide accurate quantification. Such measure-
ments were performed with a variant of the sequence described
above, also involving stimulated echo acquisition and echo planar
readout as described in [44]. Again, the sequence involved a non-
selective STEAM preparation followed by multi-slice excitation
and EPI readout. There was only one loop over slices, however. In
order to change this known multi-slice STEAM sequence [45] into
a B1 measurement [46], a non-selective pulse and appropriate
extra spoiling was inserted in the so-called mixing period of the
sequence where prepared magnetization is stored longitudinally
for a period TM. This extra pulse had a freely selectable tip angle.
Since it partially removes the stored longitudinal magnetization in
the TM period, the signal exhibits a clean cosine-dependence on
the actual tip angle of this non-selective pulse, independent of e.g.
relaxation, other tip angles, slice profiles and partial volume. This
only requires that the magnetization is equally relaxed between
sequence repetitions with different tip angles, which is ensured by
choosing a long TR. In this way, B1 was measured accurately in
75 seconds. Parameters for the B1 measurement were: in-plane
resolution 3.163.1 mm2, slice thickness 8 mm, field of view
400 mm, 15 slices (covering the entire brain), tip angle 30u (slice
selective pulse), TR 10.6 s, TM 11 ms and TE 29 ms. The two
initial STEAM tip angles were 80u and the latter 30u to ensure
near-complete recovery of the longitudinal magnetization within
the TR period. The adjustable tip angle was altered between 0u
and 350u in steps of 50u.
The B1 maps showed expected significant deviations between
nominal and actual tip angles, reflecting coil and head geometries,
and varying smoothly across tissue boundaries. The maps were
used to calculate T1 estimates free of B1 inhomogeneity in a single
compartment model.
Handling B1 inhomogeneity and fitting T1. If no B1
inhomogeneity or partial volume effects were present and the
magnetization was fully relaxed before each STEAM preparation,
the measured signal would decay exponentially as a function of
TM on a timescale depending on the longitudinal relaxation rate
and the nominal excitation tip angles. Neither of these conditions
is fulfilled, however, and the signal is therefore not easily expressed
in closed form. To keep the sequence duration short, the TR was
chosen so that not all tissue components had relaxed fully before
STEAM preparations. Due to the slice order permutations, this
gives rise to small non-trivial deviations from exponential behavior
compromising simple fitting as a means of doing T1 estimation.
Variation in tip angle furthermore results from B1 inhomogeneity
and reliable T1 estimation therefore requires B1 to be known.
Both of these effects were accounted for in a T1 estimation
performed by modeling a voxelwise fit to the measured signal
using the Levenberg-Marquardt algorithm. The spin evolution
was modeled from solutions of the Bloch equations for periods of
relaxation interrupted by hard pulses of known tip angle. The
modeling effectively filtered out additional small signal contribu-
tions coming from slice crosstalk. The resulting fits, representing
single compartment approximations to the measured signal,
provided quantitative T1 maps as well as relative proton density
maps (used for spatial normalization).
Image pre-processing. Pre-processing in the patient group:
The following procedures were performed in each patient. Lesions
were identified by simultaneous visual inspection of proton density
images, T2 weighted images and FLAIR images. Tissue classified
as lesion was marked on the FLAIR image using a semi-automatic
thresholding technique with in-house developed software (RIP,
http://www.drcmr.dk/software/downloads.html). Tissue classifi-
cation was performed by a trained observer, blind to any clinical as
well as neuropsychological data.
Automated segmentation, co-registration and reslicing were
done using SPM5 (http://www.fil.ion.ucl.ac.uk/spm/software/
spm5/). The performed tissue segmentation was based on the
MPRAGE images and resulted in only three compartments: CSF,
gray matter and white matter. Consequently, any voxel in a lesion
will falsely be categorized as either of these. However, because
lesions were excluded from our analysis of the NAWM such
misclassification would not influence our results.
The FLAIR images were coregistered to the MPRAGE using
a linear coordinate transformation with 6 parameters (3 trans-
lational and 3 rotational) and the resulting transformation matrix
applied to the lesion masks, bringing these into native space of the
MPRAGE image. A NAWM mask was constructed by excluding
the lesion masks from the white matter mask followed by a 3 mm
erosion and 1 mm dilation using the FSL software [47,48]. The
process of erosion and dilation was done to minimize partial
volume effects when going from a high resolution NAWM mask to
the low resolution T1 measurements. Using a linear trans-
formation, the MPRAGE and a standard MNI template [49]
were co-registered, allowing for automatic and robust removal of
the volume below the line from the superior surface of the anterior
Figure 6. Sequence used for T1 measurements. The applied STEAM sequence used for T1 quantification includes loops over slices (slc),
repetitions (rep) and slice orderings (slc-order).
doi:10.1371/journal.pone.0056375.g006
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commissure to the center of the posterior commissure (the AC-PC
line). This step removed the cerebellum as well as the pre-frontal
areas, the latter being subject to main field (B0) inhomogeneities.
Finally, the MPRAGE and the T1 measurement were coregis-
tered, and all analyses of the T1 maps were performed in their
native space.
Preprocessing in healthy controls: The same procedure was
applied to the MRI data sets acquired in healthy subjects except
for the steps involving the identification and exclusion of white
matter lesions. The mean T1 value and its coefficient of variation
(ratio of the standard deviation to the mean) were calculated for
the NAWM mask of patients and the white matter mask of healthy
subjects. The coefficient of variation provides a measure of
variability of the T1 value within the white matter for each
individual and was used as an index of T1 heterogeneity of the
tissue.
Statistical Analysis
The mean T1 value as estimated for NAWM in MS patients
and cerebral white matter in healthy controls was defined as
primary variable of interest. Between-group differences as well as
within-subject decreases in T1 value after Gd-DTPA injection
were statistically assessed using a two-factorial repeated measure
analysis of variance (ANOVA) with the between-subject factor
‘‘group’’ (MS patients vs. healthy controls) and the within-subject
factor ‘‘time’’ (before vs. after Gd-DTPA injection). Greenhouse-
Geisser correction for non-sphericity was applied conditional on
a significant Mauchly’s test and ANOVAs were followed by post-
hoc one-sided paired-sample t-tests to assess the decrease in T1
values after Gd-DTPA injection in each group or by two-sided
independent-samples t-tests to assess differences in T1-values
between groups. An additional ANOVA was performed using the
coefficient of variation of the T1 values as dependent variable to
assess possible effects of Gd-DTPA injection on the variability of
T1 values in the white matter. Multiple regression analysis was
performed to test for correlations between EDSS or age and T1
values before as well as after injection of contrast agent. Effect of
treatment (interferon vs. glatiramer acetate) was tested by a two-
sided independent-samples t-test. P-values ,0.05 were considered
significant. Data are presented as mean 6 SD if not specified
otherwise. Statistical analyses were performed using SPSS version
19.
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